Introduction:With the widespread use of electronic devices, myopia has become an increasingly serious issue, with projections suggesting that nearly half of the global population will be affected by 2050. The latest research has found that the caffeine metabolite 7-MX can inhibit eye axis elongation, showing promise as a new option for myopia prevention and control. This article analyzes data from a 20-year-long Danish children’s study, revealing the actual effects, safety, and future application potential of 7-MX, providing scientific insights for readers concerned about eye health.
In modern life, screens are ubiquitous. Office workers spend long hours each day staring at their phones and computers, keeping their eyes under constant high strain, which has led to a rise in myopia. Currently, around 30% of the global population suffers from myopia, and it is estimated that this proportion will climb to 50% by 2050, with a significant portion experiencing high myopia (over 500 degrees).
The worsening of myopia is primarily due to excessive elongation of the eye axis, so recent research has focused on how to effectively control such changes. While previous animal studies have shown thatthe caffeine metabolite 7-MX can slow down eye axis elongation, there has been a lack of clinical evidence in humans. Recently, however, a study published in the British Journal of Ophthalmology provided new scientific evidence for the myopia-prevention potential of 7-MX by analyzing over two decades of longitudinal data from a children's tracking study in Denmark.
The research team accessed medical records of 711 children undergoing myopia treatment from a Danish eye clinic between June 2000 and January 2021 (including 356 girls and 355 boys). Among them, 624 children took an average of 470 milligrams of 7-MX tablets daily, with some taking doses as high as 1200 milligrams, while the remaining 87 did not take the substance.
The results showed that compared to the non-users, children who consumed 400 milligrams of 7-MX per day had a reduction in eye axis growth rate of approximately0.04 millimetersin the first year; those who took 1000 milligrams per day saw a reduction of about0.07 millimeters. Over a six-year cumulative observation period, children taking 7-MX experienced roughly0.18 millimetersless total eye axis growth, a difference that may have clinical significance.
Notably, throughout the follow-up period, no significant side effects were reported among the children taking 7-MX. However, since 7-MX has a relatively short half-life in the bloodstream, commonly available immediate-release tablets—even when taken three times a day—are unlikely to maintain a stable therapeutic concentration in the body, a point to be especially mindful of in practical applications.
The researchers further pointed out that the findings of this observational study align with previous animal experiments, but certain limitations remain. These include the inability to completely rule out confounding factors such as genetic background, daily outdoor activity time, lifestyle habits, and ethnicity. Therefore, to establish a causal relationship between 7-MX and myopia control, more rigorous randomized controlled trials will be needed in the future.
If subsequent studies can successfully confirm its efficacy and safety,7-MX could become a practically valuable pharmaceutical option in the field of myopia prevention and control, offering more effective management strategies for children and adolescents.
Before technology can endow humans with “eagle eyes,” protecting the vision we already have becomes all the more crucial. In addition to keeping an eye on scientific advancements, reducing high-intensity screen time, increasing outdoor activities moderately, or even starting with a cup of coffee—these are all worthwhile strategies for eye care.
The above content is compiled by CoffeeHunters, a coffee news website.
